Chad Binns, MD
Clinical FellowAbout
Research
Publications
2025
Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review
Jacobs J, Binns T, Schlafer D, Woo J, Booth G, Adkins B. Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review. Transfusion And Apheresis Science 2025, 64: 104081. PMID: 39883995, DOI: 10.1016/j.transci.2025.104081.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraSecondary thrombotic thrombocytopenic purpuraFood and Drug Administration Adverse Event Reporting SystemAssociated with alemtuzumabThrombocytopenic purpuraMultiple sclerosisReport of thrombotic thrombocytopenic purpuraImmune-mediated thrombotic thrombocytopenic purpuraCongenital thrombotic thrombocytopenic purpuraHematopoietic stem cell transplantationFAERS databaseAnd Drug Administration Adverse Event Reporting SystemStem cell transplantationUnited States Food and Drug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemADAMTS13 deficiencyAlemtuzumab administrationCell transplantationADAMTS13 geneEvent Reporting SystemPatient demographicsAlemtuzumabCase reportTherapy indicationsCross-sectional analysis
2024
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E, Abels E, Binns T, Duque M, McQuilten Z, Mingot‐Castellano M, Savani B, Sharma D, Tran M, Tormey C, Moise K, Bloch E, Adkins B. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal Of Hematology 2024, 99: 2351-2366. PMID: 39324647, PMCID: PMC11560617, DOI: 10.1002/ajh.27487.Peer-Reviewed Original ResearchHematological conditionsFcRn inhibitorsClinical trialsStandardized treatment algorithmClinical trial dataNeonatal Fc receptorIn vivo studiesImmune-mediatedHematological disordersTreatment algorithmTransports IgGAdverse eventsImmunomodulatory/immunosuppressive therapiesIgG levelsPatient populationProtective IgGFc receptorsTherapeutic strategiesMucosal surfacesRheumatologic conditionsIgG antibodiesImmunoglobulin isotypesTrial dataIgGFcRnTherapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Yurtsever N, Binns T, Hendrickson J, Tormey C, Lee E. Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma. Lab Medicine 2024, 56: 85-88. PMID: 39038224, DOI: 10.1093/labmed/lmae054.Peer-Reviewed Original ResearchEnhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys
Piotrowski-Daspit A, Bracaglia L, Eaton D, Richfield O, Binns T, Albert C, Gould J, Mortlock R, Egan M, Pober J, Saltzman W. Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys. Nature Communications 2024, 15: 4247. PMID: 38762483, PMCID: PMC11102454, DOI: 10.1038/s41467-024-48442-7.Peer-Reviewed Original ResearchConceptsPoly(amine-co-esterPolymer nanoparticlesDelivery of nucleic acid therapeuticsCell-type tropismTissue tropismNucleic acid delivery vehiclesIn vivo deliveryIn vivo efficacyCirculation half-lifeNucleic acid therapeuticsVehicle characteristicsTunable propertiesBiodistribution assessmentPhysiological fatePolymer chemistrySurface propertiesPharmacokinetic modelTissue targetingNanoparticlesDistribution modifiersPolymeric nanoparticlesTropismPolymerDelivery vehiclesHalf-life
2023
The potential association between extracorporeal photopheresis and thrombosis
Jacobs J, Adkins B, Bibb L, Woo J, Allen E, Stephens L, Binns T, Bloch E, Booth G. The potential association between extracorporeal photopheresis and thrombosis. Bone Marrow Transplantation 2023, 59: 270-273. PMID: 37996561, PMCID: PMC11423869, DOI: 10.1038/s41409-023-02153-7.Peer-Reviewed Original ResearchPassive transfer of alloantibodies through breast milk as a mediator of hemolytic anemia
Abels E, Jacobs J, Prior D, Willets L, Sostin N, Tormey C, Binns T. Passive transfer of alloantibodies through breast milk as a mediator of hemolytic anemia. Transfusion 2023, 63: 2188-2196. PMID: 37706556, DOI: 10.1111/trf.17548.Peer-Reviewed Original ResearchConceptsMaternal breast milkBreast milkNeonatal circulationRed blood cellsPassive transferAntiviral IgG antibodiesResolution of anemiaPaucity of dataNeonatal red blood cellsIntravenous immunoglobulinMaternal alloantibodiesMaternal antibodiesPlacental transferRBC antibodiesIgG antibodiesHemolytic diseaseHemolytic anemiaPlasma titersAlloantibodiesHDFNBlood cellsAntibodiesSignificant decreasePatientsAnemiaWarm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity
Jacobs J, Binns T, Abels E, Campos J, Elkabbani R, Kress A, Sostin N, Tormey C. Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity. American Journal Of Clinical Pathology 2023, 160: 561-565. PMID: 37598315, DOI: 10.1093/ajcp/aqad095.Peer-Reviewed Original ResearchConceptsWarm autoantibodiesRed blood cellsAntigenic specificityCase of autoantibodiesCase 1Autoimmune hemolytic anemiaDirect antiglobulin testRBC transfusionPregnant womenTransfusion reactionsAntiglobulin testHemolytic anemiaAutoantibodiesRBC antigensAntibody detectionRBC unitsRare reportsBlood cellsCase 2Immunohematologic testingSignificant hemolysisRhD typingCase 3AlloantibodiesAutoantiBlood bans and COVID-19: Government attempts to influence medicine and science threaten us all
Jacobs J, Binns T, Chooljian D, Adkins B, Woo J, Stephens L, Schlafer T, Savani B, Booth G. Blood bans and COVID-19: Government attempts to influence medicine and science threaten us all. American Journal Of Clinical Pathology 2023, 160: 435-436. PMID: 37410089, DOI: 10.1093/ajcp/aqad071.Commentaries, Editorials and LettersPregnant patients with sickle cell disease and hyperhemolysis requiring intrauterine transfusion: A challenging clinical scenario
Abels E, Binns T, Sostin N, Stendahl K, Tormey C, Jacobs J. Pregnant patients with sickle cell disease and hyperhemolysis requiring intrauterine transfusion: A challenging clinical scenario. Pediatric Blood & Cancer 2023, 70: e30428. PMID: 37194476, DOI: 10.1002/pbc.30428.Peer-Reviewed Case Reports and Technical NotesEpidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review
Jacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSickle cell diseaseHyperhaemolysis syndromeAnti-globulin testRed blood cellsSupportive transfusionsIndirect anti-globulin testDirect anti-globulin testIntravenous immune globulinHaemolytic transfusion reactionsImmune globulinMedian hemoglobinClinical featuresCommon therapyUnderlying pathophysiologyTransfusion reactionsCell diseaseSevere formTherapeutic strategiesPatientsSystematic reviewBlood cellsTransfusionHyperhaemolysisDaysCorticosteroids
News
Get In Touch
Contacts
Events
May 202514Wednesday
Everyone Sean Gu, MD, PhD - Chad Binns, MD